Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of mRNA-1345 RSV Vaccine in Children 2 to <18 Years
NCT06097299Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Oct 2023
- Primary completion
- Jun 2025
- Countries
- 2
01
Overview
A Phase 2 trial of RNA-100-AR02 in respiratory syncytial virus infection (RSV), sponsored by Moderna Inc. Started Oct 2023; status: completed.
02
Drugs
RNA-100-AR02
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06097299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06097299.